Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

#ESMO21 Expert Video Report on novelties in metastatic NSCLC

Reporting from the ESMO Congress 2021, Robin Cornelissen discusses novel precision medicine strategies for patients with NSCLC. He explains the response results from the ZENITH20-4 cohort in first-line treatment with poziotinib for HER2 exon 20 mutated NSCLC and reviews promising results from the Atalante-1 phase III study, testing a vaccine strategy in patients with HLA-A2+ NSCLC after immunotherapy failure. Finally, he explains the outcomes from datopotamab deruxtecan in mNSCLC with actionable genomic alterations by detailing the encouraging results from the TROPION-PanTumor01 study.

Abstracts:
LBA46 - Efficacy and Safety of Poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational Phase 2 study (ZENITH20-4) - Dr Robin Cornelissen, NL
LBA47 - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Final results of Phase 3 Atalante-1 randomised trial - Prof Benjamin Besse, FR
LBA49 - Outcomes in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs) from the phase 1 TROPION-PanTumor01 study of datopotamab deruxtecan (Dato-DXd) in solid tumors - Dr Edward Garon, US

This video is part of a sponsored track. The study results covered, and the presenter of this expert video, have been selected exclusively by ESMO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings